XELTIS
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for which clinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands ... and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.
XELTIS
Industry:
Health Care Medical Device Therapeutics
Founded:
2006-01-01
Address:
Eindhoven, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.xeltis.com
Total Employee:
11+
Status:
Active
Contact:
+31407517614
Email Addresses:
[email protected]
Total Funding:
115.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Nginx Google Google Cloud Google Cloud London
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Brainsgate
BrainsGate is a medical device company developing innovative therapies for patients suffering from central nervous system diseases.
Channel Medsystems
Channel Medystems is a clinical-stage medical technology engaged in the development of proprietary cryo-ablation delivery technologies.
Corwave
CorWave is a medical device company developing innovative heart pumps.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Current Advisors List
Current Employees Featured
Founder
Investors List
China Grand Pharmaceutical and Healthcare Holdings
China Grand Pharmaceutical and Healthcare Holdings investment in Series D - Xeltis
European Investment Bank
European Investment Bank investment in Debt Financing - Xeltis
LSP
LSP investment in Series D - Xeltis
VI Partners
VI Partners investment in Series C - Xeltis
Ysios Capital
Ysios Capital investment in Series C - Xeltis
Life Sciences Partners
Life Sciences Partners investment in Series C - Xeltis
Kurma Partners
Kurma Partners investment in Series C - Xeltis
Life Sciences Partners
Life Sciences Partners investment in Series B - Xeltis
VI Partners
VI Partners investment in Series B - Xeltis
Kurma Partners
Kurma Partners investment in Series B - Xeltis
Official Site Inspections
http://www.xeltis.com Semrush global rank: 9.47 M Semrush visits lastest month: 152
- Host name: 25.26.205.92.host.secureserver.net
- IP address: 92.205.26.25
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Xeltis"
About - Xeltis
Xeltis is a medtech company developing transformative vascular implants that enable the natural creation of living and long-lasting tissue. ... Currently his scientific interest focuses mostly on …See details»
Xeltis - Crunchbase Company Profile & Funding
Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment …See details»
Xeltis Company Profile 2024: Valuation, Funding
Xeltis General Information Description. Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow …See details»
Careers - Xeltis
Xeltis is a medtech company developing transformative vascular implants that enable the natural creation of living and long-lasting tissue. Visit our About page to learn more. About. Xeltis De Lismortel 31 5612 AR Eindhoven The …See details»
Xeltis Company Profile - Office Locations, Competitors, Revenue
Xeltis has 5 employees across 3 locations and $119.53 m in total funding,. See insights on Xeltis including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Xeltis - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Xeltis - EQT Group
Latest news. 22 November 2024 EQT to sell Melita, the digital infrastructure owner and operator in Malta; 18 November 2024 EQT Life Sciences leads €54 Million Series A Financing of ATB TherapeuticsSee details»
Xeltis announces FDA Breakthrough Device Designation for …
Nov 14, 2024 Xeltis' groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its …See details»
Xeltis announces FDA Breakthrough Device Designation for …
Nov 14, 2024 EINDHOVEN, The Netherlands, 14 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, …See details»
Xeltis receives IDE approval from FDA for initiation of US pivotal ...
Jun 13, 2024 Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US …See details»
Xeltis raises €32 million to drive clinical development of
Feb 21, 2023 Xeltis is based in The Netherlands and the USA and its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, and Ysios Capital, as well as …See details»
Xeltis expands leadership team with appointment of Luc Verhees …
Nov 5, 2024 Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has appointed Luc Verhees as its …See details»
Xeltis receives IDE approval from FDA for initiation of US pivotal ...
Jun 13, 2024 Xeltis' groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its …See details»
Xeltis expands leadership team with appointment of Luc Verhees …
Nov 5, 2024 Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its …See details»
Xeltis presents excellent six-month first-in-human data
Apr 28, 2023 Xeltis Eliane Schutte, CEO Alexander Goemans, CFO [email protected]. Consilium Strategic Communications Amber Fennell / Chris Welsh +44 (0) 20 3709 5700 …See details»
Xeltis wins FDA breakthrough status, enrols first patient in pivotal ...
Nov 14, 2024 Xeltis says the device is designed to reduce infection and reintervention rates compared to existing arteriovenous rafts and to improve vascular access options in patients …See details»
News & Events - Xeltis
Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial Designation recognizes aXess has the potential of providing a more effective …See details»
Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative ...
Jul 8, 2021 “The Xeltis pulmonary heart valve is the most advanced heart valve with regenerative properties based only on a biocompatible synthetic structure and the first ever …See details»
Xeltis receives IDE approval from FDA for initiation of US pivotal ...
Jun 13, 2024 EINDHOVEN, The Netherlands, 13 June 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, …See details»